Amneal Pharmaceuticals (AMRX) is a global specialty pharmaceutical leader delivering wholesale distribution and contract manufacturing services with a recent return to profitability and strong revenue expansion.
Investors should consider AMRX as a compelling turnaround play given the company's return to profitability after four years of losses. The substantial cash position of $282.0M and positive operating cash flow provide flexibility for debt reduction or strategic acquisitions. With revenue growing consistently from $2.21B in 2022 to $3.02B in 2025, the company demonstrates strong market demand and operational scalability.
The company carries a net negative shareholders' equity of -$71.3M and high long-term debt levels that may constrain future growth or limit share repurchase programs. Volatile non-operating income losses of $-254.9M suggest potential sensitivity to market conditions or accounting adjustments that could impact reported earnings. The retail pharmacy sector's structural decline and ongoing drug price negotiations present headwinds that could suppress future revenue growth rates.
Amneal Pharmaceuticals Inc. is a leading specialty pharmaceutical manufacturer and distributor serving global markets with a diverse portfolio of injectable, oral, and ophthalmic products. The company operates across multiple segments including wholesale distribution, contract manufacturing, and branded generics, leveraging its extensive network to deliver cost-effective therapies. Recent financial performance highlights a significant turnaround from prior losses to a net profit of $127.9M in 2025, driven by robust revenue growth reaching $3.02B.
Management successfully executed a strategic turnaround, evidenced by the shift from a $-254.8M loss in 2022 to a $127.9M net profit in 2025. Operating cash flow of $340.0M demonstrates strong liquidity generation despite significant capital expenditures of $70.1M and investing outflows of $112.3M. The reduction in accumulated other comprehensive income loss and the improvement in retained earnings deficit indicate effective cost management and revenue optimization.
The global specialty pharmaceuticals industry is characterized by high barriers to entry, stringent regulatory requirements, and a shift towards value-based care models. Companies in this space are increasingly focusing on contract manufacturing and distribution partnerships to navigate patent expirations and generic competition. Consolidation is a key trend as smaller players seek scale or exit strategies amidst margin compression.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $2.21B | $2.39B | $2.79B | $3.02B |
| Cost of Revenue | $1.42B | $1.57B | $1.77B | $1.91B |
| Gross Profit | $784.7M | $820.6M | $1.02B | $1.11B |
| Operating Expenses | $879.6M | $616.2M | $771.1M | $719.2M |
| Operating Income | $-94.9M | $204.4M | $249.3M | $394.1M |
| R&D | $195.7M | $163.9M | $190.7M | $186.2M |
| G&A | $399.7M | $429.7M | $476.4M | $526.8M |
| Stock-Based Comp | $31.8M | $26.8M | $27.8M | $32.0M |
| Depreciation | $68.1M | $66.2M | $62.6M | $57.3M |
| Amortization | $172.1M | $163.2M | $173.6M | $166.3M |
| Other OpEx | $284.2M | $22.6M | $104.0M | $6.2M |
| Non-Operating Income | $-153.2M | $-244.6M | $-304.3M | $-254.9M |
| Pre-Tax Income | $-248.1M | $-40.3M | $-55.0M | $139.2M |
| Income Tax | $6.7M | $8.5M | $18.9M | $11.3M |
| Continuing Ops | $-254.8M | $-48.7M | $-73.9M | $127.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-254.8M | $-48.7M | $-73.9M | $127.9M |
| Minority Interest | $-125.2M | $35.3M | $43.0M | $55.9M |
| Net to Common | $-129.5M | $-84.0M | $-116.9M | $72.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.41B | $1.38B | $1.59B | $1.91B |
| Cash & Equivalents | $26.0M | $91.5M | $110.6M | $282.0M |
| Accounts Receivable | $741.8M | — | — | — |
| Inventory | $530.7M | $581.4M | $612.5M | $606.3M |
| Prepaid Expenses | $103.6M | $82.7M | $80.7M | $98.4M |
| Other Current Assets | $9.8M | $622.3M | $784.1M | $924.5M |
| Long-Term Assets | $2.39B | $2.09B | $1.91B | $1.77B |
| PP&E (Net) | $469.8M | $447.6M | $424.9M | $442.9M |
| Intangibles | $1.10B | $890.4M | $732.4M | $563.5M |
| Goodwill | $598.9M | $598.6M | $597.4M | $595.5M |
| Operating Leases | $56.1M | $43.3M | $42.4M | $54.0M |
| Other LT Assets | $166.6M | $114.8M | $116.6M | $111.1M |
| Total Assets | $3.80B | $3.47B | $3.50B | $3.68B |
| Current Liabilities | $752.8M | $846.6M | $1.13B | $881.6M |
| Accounts Payable | $166.0M | — | — | — |
| Current Debt | $30.0M | $34.1M | $224.2M | $6.8M |
| Other Current Liab | $556.9M | $812.5M | $905.6M | $874.9M |
| Long-Term Liabilities | $2.86B | $2.61B | $2.48B | $2.87B |
| Long-Term Debt | $2.59B | $2.39B | $2.16B | $2.57B |
| Other LT Liab | $210.6M | $41.0M | $219.4M | $302.9M |
| Total Liabilities | $3.62B | $3.45B | $3.61B | $3.75B |
| Shareholders' Equity | $184.0M | $20.0M | $-109.5M | $-71.3M |
| Paid-In Capital | $691.6M | $539.2M | $560.2M | $571.8M |
| Retained Earnings | $-406.2M | $-490.2M | $-607.1M | $-535.0M |
| AOCI | $9.9M | $-32.3M | $-65.5M | $-110.7M |
| Total L&E | $3.80B | $3.47B | $3.50B | $3.68B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-254.8M | $-48.7M | $-73.9M | $127.9M |
| Non-Cash Adjustments | $35.7M | $516.3M | $-214.2M | $-37.0M |
| Working Capital Changes | $284.2M | $-122.0M | $583.2M | $249.0M |
| Cash from Operations | $65.1M | $345.6M | $295.1M | $340.0M |
| Capital Expenditures | $46.4M | $43.2M | $51.9M | $70.1M |
| Cash from Investing | $-174.3M | $-69.2M | $-63.0M | $-112.3M |
| Cash from Financing | $-106.6M | $-212.6M | $-211.8M | $-31.5M |
| FX Effect | $-5.7M | $65.0K | $-999.0K | $-1.7M |
| Net Change in Cash | $-221.5M | $63.9M | $19.3M | $194.5M |
| Beginning Cash | $256.7M | $35.2M | $99.1M | $118.4M |
| Ending Cash | $35.2M | $99.1M | $118.4M | $312.9M |
The company's revenue streams are primarily derived from its Wholesale Distribution segment, which handles the sourcing and supply of prescription drugs to healthcare providers. A significant portion of earnings also comes from Contract Manufacturing Services, where Amneal provides sterile injectable and oral production capabilities for other pharmaceutical firms. Additionally, the portfolio includes Branded Generics and Ophthalmic products, contributing specialized revenue through proprietary formulations and distribution partnerships.
The pharmaceutical industry faces intense pricing pressure from payers and regulators that could erode gross margins on generic products. Regulatory changes regarding drug pricing, patent cliffs, or supply chain disruptions for key raw materials pose significant operational risks. High levels of debt relative to equity ($2.57B long-term debt vs -$71.3M shareholders' equity) create refinancing risks in a rising interest rate environment.
Amneal possesses a massive global network of manufacturing sites and distribution centers that provide unparalleled economies of scale and supply chain resilience. Its diversified product portfolio across injectables, ophthalmics, and oral medications reduces reliance on any single therapeutic area or customer base. The company benefits from strong regulatory relationships and established partnerships with major healthcare systems, ensuring stable long-term demand.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.